SOURCE: Active Biotech

November 18, 2008 02:10 ET

Teva Completes Enrollment in Laquinimod Phase III Clinical Trial

LUND, SWEDEN--(Marketwire - November 18, 2008) -


- Recruitment Still Ongoing For Second, Pivotal Phase III Study, Bravo -

Jerusalem, Israel and Lund, Sweden, November 18, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completion of patient enrollment for the Phase III clinical trial, Allegro, in relapsing-remitting multiple sclerosis (RRMS). The pivotal Allegro study is designed to evaluate the efficacy, safety and tolerability of the oral investigational compound, laquinimod, versus placebo in the treatment of RRMS.

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on November 18, 2008, at 8:00 a.m.

Contact:
Elana Holzman, Teva Pharmaceutical Industries Ltd.,  +972 3 926-7554
Kevin Mannix,  Teva North America, +1 215 591-8912
Tomas Leanderson, Active Biotech AB, +46 46 19 20 95
Göran Forsberg, Active Biotech AB, +46 46 19 11 54

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Teva Completes Enrollment in Laquinimod Phase III Clinical Trial: http://hugin.info/1002/R/1270575/281461.pdf

Copyright © Hugin AS 2008. All rights reserved.

Contact Information